| Identification | Back Directory | [Name]
4-Piperidinone, 3,5-bis[(2-fluorophenyl)methylene]-1-[[1-[(4-fluorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methyl]-, (3E,5E)- | [CAS]
1983924-33-9 | [Synonyms]
4-Piperidinone, 3,5-bis[(2-fluorophenyl)methylene]-1-[[1-[(4-fluorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methyl]-, (3E,5E)- | [Molecular Formula]
C29H23F3N4O | [MOL File]
1983924-33-9.mol | [Molecular Weight]
500.51 |
| Hazard Information | Back Directory | [Description]
CT-1 is a novel orally active DNA minor groove ligand, against breast cancer by targeting tumor DNA damage leading to p53-dependent apoptosis. | [Uses]
Anticancer agent 253 (Compound 26) has anti-cancer activity against breast cancer cells, with IC50s of 6 μM (MCF-7), 10 μM (MDA-MB-231) and 6.4 μM (4T1 cells). Anticancer agent 253 arrests cell cycle and induces mitochondria-mediated apoptosis in cancer cells. Anticancer agent 253 inhibits Akt phosphorylation in human breast and prostate cancer[1]. | [References]
[1] Mandalapu D, et al. Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines. Bioorg Med Chem Lett. 2016 Sep 1;26(17):4223-32. DOI:10.1016/j.bmcl.2016.07.053 |
|
|